Previous Close | 1.4600 |
Open | N/A |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 42.50 |
Expire Date | 2024-12-20 |
Day's Range | 1.4600 - 1.4600 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Insmed Inc (INSM) reports robust financial performance and outlines strategic initiatives for upcoming product launches amid competitive challenges.
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from th